Maternal hypertension roadmap, colon cancer treatment approval and Viatris’ proposed Pacira acquisition.
Maternal health
WHO launches roadmap to tackle hypertension in pregnancy
WHO and partners launched a global roadmap covering research, screening, medicines and emergency care for hypertensive disorders of pregnancy. The initiative addresses persistent gaps in blood-pressure monitoring, diagnostics, essential medicines and referral systems, alongside underinvestment in new treatments.
Why it matters: Highlights practical priorities for maternal-care teams, health-system planners and pharmaceutical suppliers, particularly in resource-limited settings.
FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer
The FDA approved atezolizumab with fluoropyrimidine- and oxaliplatin-based chemotherapy as adjuvant treatment for Stage III mismatch repair deficient colon cancer. In the ATOMIC trial, the combination improved disease-free survival compared with chemotherapy alone, with a hazard ratio of 0.50; median disease-free survival was not reached in either group.
Why it matters: Expands US-approved treatment options for a biomarker-defined cancer population, reinforcing the importance of mismatch repair testing and multidisciplinary treatment planning.
Viatris agrees $1.65 billion acquisition of Pacira
Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an equity value of approximately $1.65 billion. The proposed acquisition adds the non-opioid pain products Exparel and Zilretta; completion is expected by year-end 2026, subject to regulatory and other closing conditions.
Why it matters: Signals Viatris’ continued expansion into innovative branded medicines and creates potential opportunities to broaden access to its pain-management portfolio.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.